The €173 million (US$187 million) in capital that Earlybird Health recently raked in from investors will go towards bolstering investment in European health care startups, many of which are still recovering from the impact of COVID-19, Thom Rasche, a partner at Earlybird Health, told BioWorld. The fund is looking to invest in the technologies that can improve patient care.
Germany-based Earlybird Health announced the final closing of its second fund of €173 million (around $185 million). This is more than twice the size of Earlybird's first healthcare-focused fund.
2021 was a BIG year for European VC and even surpassed what we experienced in 2020. According to the most recent Atomico Report, European startups raised $120bn in funding this year which is almost…